Leveraging Chemistry42, Insilico Nominates ISM3830 as Preclinical Candidate Targeting CBLB for Advanced Tumors Immunotherapy (VIDEO)

InSilico Medicine

Caption

Insilico nominates ISM3830, a potentially best-in-class, orally available and highly selective CBLB inhibitor with an AI‑empowered novel scaffold, as a preclinical candidate (PCC) for advanced tumor immunotherapy.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.